Kornimate/medical-research-clean huggingface dataset:
effect of prevalence of bmi on efficacy of herbal medicines in girls' sexual precocity

Conditions: Precocious Puberty

Summary: effect of prevalence of overweight and obesity(body mass index (bmi)) on efficacy of herbal medicines(ziyinxiehuo) in girls sexual precocity

herbal medicines(ziyinxiehuo) might have implications for the effects of treatment. in sexual precocity among the higher bmi girls. thus the investigator use cohort studies to confirm this hypothesis. selected children were from the precocious puberty clinic of the affiliated pediatrics hospital of fudan university. calculated according to the sample size (sample 6), the total number of cases was 192. all cases met the selected criteria. the subjects were divided into three groups according to the cut-off point of bmi of height and weight of chinese children and adolescents (girls age in 2-18). compared with children of the same age and sex, overweight group includes those bmi in the range of p85-p95, obese group includes those bmi greater than (or equal to) p95, and the girls whose bmi in the range of p5-p85 are assigned to the normal group. chinese herbs for ziyinxiehuo were used to treat girls with precocious puberty, only given by hospital preparation, drug dose: 30ml/once, 3 times a day. a course of treatment lasts for three months. in this study, two courses of treatment (6 months） were observed. the subjects would received three examinations: before taking the drug (baseline), the third month (metaphase) and the sixth month (end point).

Eligibility criteria:
inclusion criteria: - no abnormal weight and height in parents and families, no organic diseases, no drugs affecting gonadal axis or obesity; normal health, no secondary obesity caused by endocrine and genetic metabolic diseases, no lifestyle intervention to treat obesity. exclusion criteria: - central neoplastic lesions, rare syndrome, severe heart, liver and kidney diseases and other chronic diseases such as tuberculosis, asthma, rheumatism, complicated infection, congenital hypothyroidism associated with precocious puberty, peripheral precocious puberty, incomplete precocious puberty and so on.

Keywords: puberty
study comparing cyclosporin dose reduction with cyclosporin elimination in kidney transplant recipients taking sirolimus

Conditions: Kidney Disease

Summary: to assess equivalence in the rates of functional graft survival at 12 months after transplantation in patients receiving induction therapy with cyclosporin (csa, neoral) and rapamune® followed by csa dose reduction and concentration-controlled rapamune® versus induction with csa and rapamune® followed by discontinuation of csa and concentration-controlled rapamune®.


Eligibility criteria:
inclusion criteria: * age: = to ≥ 18 years. * end-stage renal disease, with patients scheduled to receive a primary or secondary renal allograft from a cadaveric donor, from a living-unrelated donor, or from a living-related donor. * patients with second and subsequent transplants must have maintained their primary graft for at least 6 months after transplantation (with the exception of graft failure due to technical reasons). exclusion criteria: * evidence of active systemic or localised major infection prior to initial rapamune® administration. * evidence of infiltrate, cavitation, or consolidation on chest x-ray obtained during screening. * use of any investigational drug or treatment up to 4 weeks prior to enrolling in the study and during the 12-month treatment phase. exception: the use of erythropoiesis stimulating products. in these cases, erythrocyte-stimulating products must be discontinued prior to administration of rapamune®.

Keywords: kidney disease
oral iron supplementation for patients with chronic kidney disease

Conditions: Chronic Renal Disease; Iron-Deficiency Anemia; Anemia of Chronic Kidney Disease; Dysbiosis

Summary: the hypothesis of this research is that oral iron prescribed in a single dose in alternate day could mitigate the side effects with regard to intestinal microbiota, inflammation, oxidative stress and improve the hematological profile when compared to daily oral iron prescription

chronic kidney disease triggers several changes in the body, anemia is one of the first disorders that appear in chronic kidney disease patients. the anemia in this patient is multifactorial, the main cause being relative erythropoietin deficiency, although iron deficiency is also common. in this context, the need for oral iron supplementation is a way of both treating iron deficiency and optimizing the use of agents that stimulate erythropoiesis. however, this replacement can cause iron overload, increasing the production of reactive oxygen species and, consequently, oxidative stress, and also alter the intestinal microbiota leading to poor iron absorption, worsening the prognosis of chronic kidney disease. the current routine for iron supplementation for these patients is to offer oral iron daily, which can be more harmful than when given on alternate days. however, there are few studies comparing the two prescriptions. in this context, since no study to date has been carried out to show the aforementioned effects in the participant with chronic kidney disease, this randomized clinical trial aims to assess the effects of daily or alternate-day oral iron supplementation on gut microbiota composition in participants with chronic kidney disease (glomerular filtration rate (gfr) below 30 ml/min) for 3 months. the project will also compare the effects of both prescriptions on serum hepcidin levels, markers of oxidative stress and inflammation, and on routine hematological and biochemical parameters.

Eligibility criteria:
inclusion criteria: aged 18 to 75 years clinical diagnosis of chronic kidney disease conservative treatment group: chronic kidney disease stages 3 and 5 exclusion criteria: * patients pregnant * smokers * using antibiotics in the last 3 months * autoimmune diseases * clinical diagnosis of infectious diseases * clinical diagnosis of cancer * clinical diagnosis of aids

Keywords: hepcidin inflammation
effect of acupressure-ice message on primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: this study will be conducted to determine the effect of acupressure ice massage on primary dysmenorrhea.

dysmenorrhea is considered the most common gynecological complaint by young women and affects approximately 60-80% of the female population. around 8-18% of that population report intense discomfort, causing absenteeism in several daily activities while suffering pain. analgesics are considered the first line of treatment, but they are known for their undesirable effects such as renal, cardiovascular and gastrointestinal complications that can negatively affect patients' health. physical therapy has alternative techniques that assist in analgesia in a practical and effective way; among them is acupressure and cryo therapy. the effect of application of ice on the skin has a direct action on neurons and pain receptors, lowering the speed and the number of nerve impulses. this effect is due to its action on the gate control of pain mechanism, leading to the release of endorphins and enkephalins that are pain-relieving substances. it was proved from previous studies that using ice massage on l14 or sp6 points reduce pain intensity in females suffering from pd. so, further studies are needed to investigate the effect of acupressure ice massage not only on pain intensity but also on other symptoms severity and quality of life of females suffering from pd. therefore, this study will be conducted for this issue which will be of valuable benefits for medical service organization and increase body of knowledge of physical therapy in scientific field.

Eligibility criteria:
inclusion criteria: * fifty adolescents' females who are clinically diagnosed as primary dysmenorrhea. * their ages will be ranged from 17-25 years old. * their bmi will be less than 30 kg/m². * all of them are virgin. * their pain level will be more than 3 on visual analogue scale. * having mild to moderate score on menstrual distress questionnaire (mdq) ( ≥ 50). * having regular menstruation for the last 6 months (every 28-30 days with no intermittent bleeding). exclusion criteria: * systematic chronic diseases or any pelvic inflammatory diseases. * secondary dysmenorrhea. * menstrual irregularity. * nerve damage resulting in loss of feeling. * swelling, scar or skin infection. * diabetic patients.
german observational multicenter study of patients with fabry disease under enzyme replacement therapy with pegunigalsidase-alfa

Conditions: Fabry Disease

Summary: pegunigalsidase-alfa may represent an advance in ert for fd, based on its unique pharmacokinetics and apparent low immunogenicity. the objective of the study is to document long term data on treatment with pegunigalsidase-alfa under "real world" conditions. 60 patients with fd (therapy-naïve or pretreated with agalsidase-alfa or agalsidase-beta) will be recruited in 8 german fabry centers. the treatment duration/patient will be 2 years. all patients will be followed-up by the above listed fabry expert centers.

pegunigalsidase-alfa, a novel pegylated, covalently crosslinked form of α-galactosidase a developed as enzyme replacement therapy (ert) for fabry disease (fd), was designed to increase plasma half-life and reduce immunogenicity, thereby enhancing efficacy compared with available products. the rationale of the current project is that disease progression of patients with fd can be stabilized comparable to patients under current ert, leading to a validation of the clinical phase 3-studies and a transfer of these previous outcomes to a nationwide "real world" designed study in germany.

Eligibility criteria:
inclusion criteria: * males and females, ≥18 years, diagnosed with fabry disease. * ert naïve (patients with signs of organ involvement (kidney, heart and/or cns signs) to be considered for ert following the european consensus guidelines on ert (biegstraaten et al. 2015) or patients with neuropathic pain not controlled with pain medication or patients with gi symptoms not relieved with standard medication or ert switch patients (under ert for ≥12 months). * subjects taking ace inhibitors, arbs, or renin inhibitors on a stable dose for at least 4 weeks before screening. * subjects taking analgesics/antidepressants on a stable dose for at least 4 weeks before screening. * female patients must have a negative pregnancy test and use a medically accepted form of contraception throughout the study. exclusion criteria: * patient is unwilling to give informed consent. * patient is unable to comply with the clinical protocol. * patients on dialysis. * patient has a clinically significant organ disease (e.g., cancer in the past 5 years) that in the opinion of the investigator would preclude participation in the trial. * patients with a history of organ transplantation.

Keywords: pegunigalsidase-alfa
exercise capacity and daily physical activity in obese subjects with treated obstructive sleep apnea

Conditions: Obstructive Sleep Apnea; Obesity

Summary: obesity is very common worldwide and breathing problems at night (obstructive sleep apnea, osa) are common in obesity. despite the best treatment, obesity and osa are linked to early death from heart problems. they are also associated with lower levels of physical activity. exercise strategies for weight loss, increasing physical activity and improving fitness are needed for obesity. in obese individuals with osa 1. the investigators will compare corridor walking tests compared to laboratory exercise tests. the null hypothesis is that the peak oxygen uptake achieved and the cardiopulmonary response during both the six-minute walk test and incremental shuttle walk test would not be different from that observed during an incremental treadmill test. 2. the investigators will investigate whether cycling or walking uses more calories for the same intensity. we hypothesise that cycling (weight supported) will be endured for long. 3. the investigators will compare commonly used exercise tests with levels of daily physical activity. the information from these three projects will help us set up the optimal exercise program for obese individuals.


Eligibility criteria:
inclusion criteria: * obstructive sleep apnea * obesity bmi\>30 * controlled on continuous positive airway pressure for three months exclusion criteria: * cardiac co-morbidity e.g ischaemic heart disease, chronic heart failure, valvular heart disease * pulmonary co-morbidity * neurological condition limiting the ability to perform walking or cycling * orthopaedic condition limiting the ability to perform walking or cycling

Keywords: obesity obstructive sleep apnea exercise walking tests cardiopulmonary exercise tests physical activity
bilateral total knee arthroplasty vs unicompartment arthroplasty retrospective and clinical outcome study

Conditions: Osteoarthritis

Summary: to determine if there is a patient satisfaction preference of total knee arthroplasty (tka) vs unicompartmental knee arthroplasty (uka) in patients with bilateral knee osteoarthritis who underwent a primary tka one side and a primary uka on the opposite side and are at a minimum of two years post-surgery. patient reported outcomes and data with be analyzed along with all retrospective chart data.


Eligibility criteria:
inclusion criteria: 1. must be able to read, understand and provide written informed consent on the institutional review board (irb) approved informed consent form (icf) 2. ability to understand and provide written authorization for use and disclosure of personal health information 3. subject who are able and willing to comply with the study protocol and follow-up visit 4. must be 18 years or older to participate 5. subjects must have a clinically documented osteoarthritis in both knees, single or multiple compartments 6. subjects must have undergone a primary tka and primary uka in the contralateral knee 7. must be a minimum 2 year (24 months) post-surgery on each knee 8. one or both tka/uka surgeries must have been performed by the principal investigator. 9. subjects must be able to return for the follow-up appointment, and have the mental capacity to cooperate with pro's, questionnaires, physical exam and radiographs exclusion criteria: 1. subjects who underwent uka with patella femoral joint (pfj) replacement on the same side. 2. women who are pregnant

Keywords: total knee replacement unicompartment knee replacement
comparative effects of cognitive and motor dual task training on balance and quality of life in parkinson's patients

Conditions: Parkinson Disease; Balance; Distorted; Postural; Defect

Summary: to compare effects of cognitive and motor dual task training on balance and quality of life in parkinson's patients

this study will be conducted to compare the comparative effect of cognitive and motor dual task training on balance and quality of life in parkinson's patients. total 20 patients will be recruited according to the inclusion criteria and data will be collected from the riphah rehabilitation center lahore, muhammadi medical trust hospital lahore. time up and go test (tug) parkinsons disease questionnaire 39 (pdq-39) will be used as data collection tool. to assess the balance and quality of life in parkinson's patients. patients will be allocated to intervention group by randomization. after approval from ethical committee, data collection will be started and informed consent will be taken from all patients

Eligibility criteria:
inclusion criteria: * a stage i-ii-iii hoehn and yahr scale consultant neurologist's diagnosis of parkinson's disease * a stable medication schedule both before and during the trial period * can walk without assistive aid exclusion criteria: * other neurological conditions in additions to parkinson's disease such as cva, head injuries, trauma * any musculoskeletal condition e.g., total knee replacement surgery and rheumatoid arthritis * sensory impairments (vestibular dysfunctions)

Keywords: parkinson disease balance; distorted postural; defect
cetuximab monotherapy maintenance treatment in mcrc

Conditions: Colorectal Cancer

Summary: investigating the efficacy of cetuximab monotherapy versus continuation after induction treatment with chemotherapy + cetuximab in inoperable or irresectable and non-progressive metastatic colorectal cancer after first line induction treatment for 24 weeks with mfolfox6/folfiri and cetuximab treatment. reinduction treatment will be done in case of progression.

investigating the efficacy of cetuximab monotherapy versus continuation after induction treatment with chemotherapy + cetuximab in inoperable or irresectable and non-progressive metastatic colorectal cancer after first line induction treatment for 24 weeks with mfolfox6/folfiri and cetuximab treatment. reinduction treatment will be done in case of progression. this treatment is continued until progression or severe toxicity.

Eligibility criteria:
inclusion criteria: * histological proof of colorectal cancer (in case of a single metastasis, histological or cytological proof of this lesion should be obtained); * distant metastases (patients with only local recurrence are not eligible); * unidimensionally measurable disease (\> 1 cm on spiral ct scan or \> 2 cm on chest x-ray; liver ultrasound is not allowed). serum cea may not be used as a parameter for disease evaluation; * in case of previous radiotherapy, at least one measurable lesion should be located outside the irradiated field; * ongoing or planned first line treatment with 6 cycles of mfolfox6/folfiri plus cetuximab. at randomisation: * who performance status 0-1 (karnofsky ps \> 70%); * laboratory values obtained ≤ 2 weeks prior to randomisation: * adequate bone marrow function (hb \> 6.0 mmol/l, absolute neutrophil count \> 1.5 x 109/l, platelets \> 100 x 109/l), * renal function (serum creatinine ≤ 1.5x uln and creatinine clearance, cockroft formula, \> 30 ml/min), * liver function (serum bilirubin ≤ 2 x uln, serum transaminases ≤ 3 x uln without presence of liver metastases or ≤ 5x uln with presence of liver metastases); * negative pregnancy test in women with childbearing potential; * expected adequacy of follow-up; * institutional review board approval; * written informed consent exclusion criteria; * history or clinical signs/symptoms of cns metastases; * history of a second malignancy ≤ 5 years with the exception of adequately treated carcinoma of cervix or basal/squamous cell carcinoma of skin. exclusion criteria: * prior adjuvant treatment for stage ii/iii colorectal cancer ending within 6 months before the start of induction treatment; * any prior adjuvant treatment after resection of distant metastases; * previous systemic treatment for advanced disease.
neighborhoods, networks, depression, and hiv risk

Conditions: HIV; Depression; Drug Use

Summary: the goal of this study is to examine how social networks, neighborhood, and depression are related to hiv risk. the intervention is designed to train individuals to cope with feelings of depression or stress as a way to reduce their risk for hiv.

this study included implementation and evaluation of a small group, randomized controlled, phase ii intervention to reduce depressive symptoms and hiv risk behaviors among inner city drug users. the intervention included elements of cognitive behavioral therapy (cbt) for depression among impoverished individuals, emphasizing depressive cognitions and behaviors theorized to be associated with depression and with hiv risk behaviors among mildly to moderately depressed drug users. in addition, the study examined active drug users' social and environmental pathways to depression and subsequent hiv risk behaviors. specifically, we will hypothesized mediating/moderating effects of neighborhood characteristics, social network factors, and individual level factors on depressive symptoms and hiv risk behaviors.

Eligibility criteria:
inclusion criteria: 1. 18-55 years old 2. hiv risk behavior: 3a. injected drugs more than 3 times in the past week or 3b. snorted/sniffed heroin or cocaine or smoked crack in the past 6 months and had 1 of the following sex risks in the past 6 months: i) 2 or more sex partners ii) had a sex partner who injected drugs iii)had a sex partner who smoked crack iv) had a sex partner who was hiv+ 4. willingness to attend group sessions exclusion criteria: 1. enrolled in another hiv behavioral intervention or depression study in past the 3 years 2. enrolled in another lighthouse study in past the 5 years 3. enrolled in the formative research (phase 1) or pilot (phase 2) of the current project.

Keywords: hiv depression drug use, risk reduction
post operative pain following pulpectomy versus pulpotomy in primary molars wit irreversible pulpitis

Conditions: Irreversible Pulpitis

Summary: study will evaluate and compare post operative pain for primary molars with irreversible pulpitis after pulpotomy and pulpuectomy


Eligibility criteria:
inclusion criteria: * healthy individual * has primary tooth with irreversible pulpitis * cooperative child exclusion criteria: * mentally, physically or medically compromised children * uncooperative children
cavernous transformation of portal vein： etiology, diagnosis, management and prognosis

Conditions: Portal Vein, Cavernous Transformation Of

Summary: to observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.

to observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein. we perform montelukast (10mg, q.d., p.o.) fot the treatment of symptomatic cavernous transformation of portal vein and to observe the efficacy such as the decrease of the volume of ascites and hydrothorax.

Eligibility criteria:
inclusion criteria: * all patients with ctpv. exclusion criteria: * patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs.

Keywords: portal vein, cavernous transformation of hypertension, portal
irritable bowel syndrome hypnotherapy

Conditions: Irritable Bowel Syndrome

Summary: the primary goal of the study was whether gut focused hypnotherapy, in a group format, was successful in reduction of symptoms in patients with irritable bowel syndrome. the secondary goal was to see if any outcome predictors could be determined.

patients with irritable bowel syndrome entering a group hypnotherapy program are asked to complete a series of questionnaires at the outset, and repeat a symptom severity scale at intervals over the one year period after termination of treatment. eligibility was limited to patients with age greater than 20. outcome measures were improvement in symptom score. outcome predictors studied included quality of relationships, measured with a quality of relationship inventory and attribution of ibs to physical or emotional cause, measured with a mind-body ibs questionnaire, both administered before onset of hypnotherapy.

Eligibility criteria:
inclusion criteria: * diagnosis of irritable bowel syndrome by rome ii criteria, age 20 and older exclusion criteria: * age below 20